Portage Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial

 

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody

https://www.globenewswire.com/news-release/2025/03/27/3051025/0/en/Portage-Biotech-Reports-Promising-Preclinical-Results-in-Mesothelioma-Supporting-First-In-Human-Trial-of-PORT-7.html